drugset / Trial / NCT04013438

Luteal Phase Support During Frozen Embryo Transfer Cycle

NCT04013438 ↗

Phase 3 Completed 60 enrolled Royan Institute
RandomizedParallel-groupDouble-blindTreatment

Summary

We aimed to decrease quantity of exogenous estrogen and evaluated the success rate of ongoing pregnancy in women undergone artificial FET who have a surplus embryos at previous fertility treatment cycles. In this study, endometrial prepared with standard long GnRH protocol and for luteal phase support patients received 6 mg oral E2 and intramuscularly P 100 mg/d and embryos on day 2-3 were transferred. Control group continued E2 until 12 week of pregnancy, while for cases after identify gestational sac with heart beat (the 6 week of pregnancy) by vaginal ultrasonography, E2 will discontinued.

Timeline

Start
2017-11-01
Primary completion
2019-01-01
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Strogen Unknown 6 mg Oral

Indications